Pulmatrix (NASDAQ:PULM) Stock Crosses Below 50-Day Moving Average – Time to Sell?

Posted by Wayne Rhoads on Jun 5th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) shares crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.32 and traded as low as $1.22. Pulmatrix shares last traded at $1.32, with a volume of 13,316 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Read Our Latest Report on Pulmatrix

Pulmatrix Trading Up 2.3%

The stock has a market capitalization of $4.82 million, a PE ratio of -1.07 and a beta of 1.95. The firm’s fifty day moving average is $1.32 and its 200-day moving average is $2.36.

Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC purchased a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is owned by institutional investors.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).